EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE

Among drug-resistant epilepsies, epileptic syndromes, characterized by combination of several types of seizures, are considered to be the most difficult in terms of treatment. Lennox–Gastaut syndrome is one of them. It manifests with polymorphic seizures (tonic axial, myatonic, atypical absence seiz...

Full description

Saved in:
Bibliographic Details
Main Authors: I. O. Shchederkina, K. A. Orlova, I. E. Koltunov, M. Yu. Dorofeeva
Format: Article
Language:Russian
Published: ABV-press 2017-02-01
Series:Русский журнал детской неврологии
Subjects:
Online Access:https://rjdn.abvpress.ru/jour/article/view/185
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850040357921751040
author I. O. Shchederkina
K. A. Orlova
I. E. Koltunov
M. Yu. Dorofeeva
author_facet I. O. Shchederkina
K. A. Orlova
I. E. Koltunov
M. Yu. Dorofeeva
author_sort I. O. Shchederkina
collection DOAJ
description Among drug-resistant epilepsies, epileptic syndromes, characterized by combination of several types of seizures, are considered to be the most difficult in terms of treatment. Lennox–Gastaut syndrome is one of them. It manifests with polymorphic seizures (tonic axial, myatonic, atypical absence seizures, status epilepticus of minor motor seizures, myoclonic, generalized convulsive, and focal seizures). This is a heterogeneous disease, represented by a complex of clinical and electroencephalographic manifestations with various etiology. Current review is devoted to a novel antiepileptic drug rufinamide, which has a new mechanism of action. The drug has been registered in Russia in 2015. The authors also describe their own experience of rufinamide usage in the treatment of drug-resistant focal epilepsy as a part of multicomponent therapy for polymorphic seizures. One patient achieved clinical remission for 16 months; the second one had more than 50 % decrease in seizures frequency with a remission of drop-attacks.
format Article
id doaj-art-d2ce1cf736aa477c8344a55ace4ba906
institution DOAJ
issn 2073-8803
2412-9178
language Russian
publishDate 2017-02-01
publisher ABV-press
record_format Article
series Русский журнал детской неврологии
spelling doaj-art-d2ce1cf736aa477c8344a55ace4ba9062025-08-20T02:56:07ZrusABV-pressРусский журнал детской неврологии2073-88032412-91782017-02-01114546010.17650/2073-8803-2016-11-4-54-60139EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICEI. O. Shchederkina0K. A. Orlova1I. E. Koltunov2M. Yu. Dorofeeva3Morozov Children’s City Clinical Hospital, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaMorozov Children’s City Clinical Hospital, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaMorozov Children’s City Clinical Hospital, Moscow Healthcare Department; Peoples’ Friendship University of RussiaAcad. Yu.E. Vel’tishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaAmong drug-resistant epilepsies, epileptic syndromes, characterized by combination of several types of seizures, are considered to be the most difficult in terms of treatment. Lennox–Gastaut syndrome is one of them. It manifests with polymorphic seizures (tonic axial, myatonic, atypical absence seizures, status epilepticus of minor motor seizures, myoclonic, generalized convulsive, and focal seizures). This is a heterogeneous disease, represented by a complex of clinical and electroencephalographic manifestations with various etiology. Current review is devoted to a novel antiepileptic drug rufinamide, which has a new mechanism of action. The drug has been registered in Russia in 2015. The authors also describe their own experience of rufinamide usage in the treatment of drug-resistant focal epilepsy as a part of multicomponent therapy for polymorphic seizures. One patient achieved clinical remission for 16 months; the second one had more than 50 % decrease in seizures frequency with a remission of drop-attacks.https://rjdn.abvpress.ru/jour/article/view/185drug-resistant epilepsypolymorphic seizureslennox–gastaut syndromerufinamideinovelon
spellingShingle I. O. Shchederkina
K. A. Orlova
I. E. Koltunov
M. Yu. Dorofeeva
EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
Русский журнал детской неврологии
drug-resistant epilepsy
polymorphic seizures
lennox–gastaut syndrome
rufinamide
inovelon
title EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
title_full EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
title_fullStr EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
title_full_unstemmed EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
title_short EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
title_sort efficacy of rufinamide in the treatment of drug resistant focal epilepsies in paediatric practice
topic drug-resistant epilepsy
polymorphic seizures
lennox–gastaut syndrome
rufinamide
inovelon
url https://rjdn.abvpress.ru/jour/article/view/185
work_keys_str_mv AT ioshchederkina efficacyofrufinamideinthetreatmentofdrugresistantfocalepilepsiesinpaediatricpractice
AT kaorlova efficacyofrufinamideinthetreatmentofdrugresistantfocalepilepsiesinpaediatricpractice
AT iekoltunov efficacyofrufinamideinthetreatmentofdrugresistantfocalepilepsiesinpaediatricpractice
AT myudorofeeva efficacyofrufinamideinthetreatmentofdrugresistantfocalepilepsiesinpaediatricpractice